The latest update is out from Oncimmune Holdings ( (GB:ONC) ).
Oncimmune Holdings Plc held a General Meeting where all proposed resolutions were passed as ordinary resolutions. The resolutions included the approval of the report and accounts, the remuneration report, the appointment of an auditor, and the remuneration of the auditor. This successful meeting reflects strong shareholder support and could positively impact Oncimmune’s operations and strategic positioning in the precision medicine industry.
More about Oncimmune Holdings
Oncimmune is a precision medicine company specializing in analyzing immune interactions through the autoantibody profile. The company partners with global pharmaceutical and biotech companies, as well as contract research organizations, to discover novel biomarkers for developing targeted therapies across immune-mediated diseases. Oncimmune’s mission is to enable precision medicine by helping partners discover novel biomarkers, drug targets, and predict treatment efficacy using its cutting-edge technology platform. The company is headquartered in the UK, with facilities in Germany and business development teams in the US and Europe.
YTD Price Performance: -89.90%
Average Trading Volume: 384,918
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.62M
See more data about ONC stock on TipRanks’ Stock Analysis page.